Figures computed from official regulatory filings — .
Analysttarget 12.5 USD (+417%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 3.7% · institutions 14.63% · short 3.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CEL SCI CORP only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
82 buys113 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| TALOR EYAL | Award | $2.4K | SEC |
| KERSTEN GEERT Rtrack record | Award | $5.4K | SEC |
| PRICHEP PATRICIA Btrack record | Award | $4.3K | SEC |
| KERSTEN GEERT Rtrack record | Buy | $138K | conv 45 | SEC |
| CIPRIANO JOHN | AwardD (derivative) | $800 | SEC |
| KERSTEN GEERT Rtrack record | AwardD (derivative) | $3K | SEC |
| TALOR EYAL | AwardD (derivative) | $2.5K | SEC |
| BAILLAVOINE BRUNO JEAN-MARIE | AwardD (derivative) | $1.1K | SEC |
| Watson Robert Eugenetrack record | AwardD (derivative) | $1.1K | SEC |
| PRICHEP PATRICIA Btrack record | AwardD (derivative) | $2.3K | SEC |
| TALOR EYAL | Award | $2.4K | SEC |
| KERSTEN GEERT Rtrack record | Award | $5.4K | SEC |
| PRICHEP PATRICIA Btrack record | Award | $4.3K | SEC |
| KERSTEN GEERT Rtrack record | Buy | $360K | conv 87Unusual size | SEC |
| KERSTEN GEERT Rtrack record | Buy | $119K | conv 67 | SEC |
| TALOR EYAL | Award | $2.4K | SEC |
| PRICHEP PATRICIA Btrack record | Award | $4.3K | SEC |
| KERSTEN GEERT Rtrack record | Award | $5.4K | SEC |
| KERSTEN GEERT Rtrack record | Buy | $200K | conv 71Unusual size | SEC |
| PRICHEP PATRICIA Btrack record | Award | $4.3K | SEC |
| TALOR EYAL | Award | $2.4K | SEC |
| KERSTEN GEERT Rtrack record | Award | $5.2K | SEC |
| KERSTEN GEERT Rtrack record | Buy | $50K | conv 45 | SEC |
| TALOR EYAL | Award | $2.4K | SEC |
| KERSTEN GEERT Rtrack record | Award | $5.2K | SEC |